144 related articles for article (PubMed ID: 16945414)
21. Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia.
Fujisaki T; Otsuka T; Gondo H; Okamura T; Niho Y; Ohhinata A; Abe F
Int Immunopharmacol; 2003 Jun; 3(6):901-7. PubMed ID: 12781706
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Chen ZX; Kaeda J; Saunders S; Goldman JM
Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
[TBL] [Abstract][Full Text] [Related]
24. A nested RT-PCR assay to detect BCR/abl.
Wasserman LM
Methods Mol Med; 2004; 97():181-9. PubMed ID: 15064493
[No Abstract] [Full Text] [Related]
25. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.
Jones CD; Yeung C; Zehnder JL
Am J Clin Pathol; 2003 Jul; 120(1):42-8. PubMed ID: 12866371
[TBL] [Abstract][Full Text] [Related]
27. Control genes in international standardization of real-time RT-PCR for BCR-ABL.
Moravcová J; Rulcová J; Poláková KM; Klamová H
Leuk Res; 2009 Apr; 33(4):582-4. PubMed ID: 18653236
[No Abstract] [Full Text] [Related]
28. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
29. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
[TBL] [Abstract][Full Text] [Related]
30. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
[TBL] [Abstract][Full Text] [Related]
31. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Sugimoto T; Ijima K; Hisatomi H; Murayama T; Mizuno I; Hato A; Imoto S; Nishimura R; Koizumi T
Am J Hematol; 2004 Oct; 77(2):164-6. PubMed ID: 15389825
[TBL] [Abstract][Full Text] [Related]
32. Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.
Moravcova J; Regner J; Mouckova D; Fiser K; Zmekova V; Malacova R; Michalova K; Klamova H
Neoplasma; 2005; 52(2):119-25. PubMed ID: 15800710
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
34. [Effect of co-expressing M-bcr/abl and m-bcr/abl fusion gene transcripts on the clinical features of patients with chronic myelogenous leukemia at diagnosis].
Meng WT; Liu T; Li JJ; Shi Q; Yu J; Cui X; Wu Y; Xiang B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):97-100. PubMed ID: 16468653
[TBL] [Abstract][Full Text] [Related]
35. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
36. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
Müller MC; Erben P; Saglio G; Gottardi E; Nyvold CG; Schenk T; Ernst T; Lauber S; Kruth J; Hehlmann R; Hochhaus A;
Leukemia; 2008 Jan; 22(1):96-102. PubMed ID: 17943168
[TBL] [Abstract][Full Text] [Related]
37. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
38. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
39. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
40. [Effects of IFN-alpha combined with IL-6 on cell growth and related genes expression and apoptosis of bone marrow cells from CGL patients].
Chen H; Tang L; Peng X; Luo Z; Luo S; Tan W
Zhonghua Xue Ye Xue Za Zhi; 2000 Jul; 21(7):341-4. PubMed ID: 11877000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
